Literature DB >> 17496391

Successful kidney transplantation does not reverse the coagulopathy in patients with chronic renal failure on either hemo or peritoneal dialysis.

A Ballow1, A M A Gader, S Huraib, A Mitwalli, F Al-Suleimani, J Al-Wakeel.   

Abstract

There is wide disagreement about the measurement of various hemostatic parameters in patients with chronic renal failure (CRF) concerning treatment with either hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). This study aims to characterize the coagulopathy in patients with CRF both before initiating dialysis, when the patients are expected to have a steady hemostatic state and after starting regular HD or CAPD. The measurements were repeated in a group of patients who received a successful renal transplant to see whether the coagulopathy associated with CRF would be corrected by this lasting therapy. The study, which was mainly cross-sectional and prospective, included two groups: 49 patients with CRF with their age ranging from 17 to 67 years were divided as follows: those on regular HD (n=20), CAPD (n=9) and patients after transplant (n=20). The tests were also done on 34 healthy controls. Significant hyper-fibrinogenemia was recorded in all three study groups. The HD group showed significant elevation in the plasma levels of AT III and total protein S and a significant reduction in free protein S and protein C, when compared with healthy controls. These inhibitors, except total PS, displayed similar fluctuations in the CAPD group. In the transplant patients, there was significant elevation of AT III and total protein S, a reduction in free PS and no significant changes in PC levels. A significant elevation was found in the levels of F1+2, TAT and D-Dimer in HD and in transplant patients, when compared with controls. In CAPD patients, only D-Dimer levels showed a significant increase. The tPA and PAI-1 levels in the three study groups were similar to the control group. Our study revealed significant activation of the hemostatic system, more pronounced in patients on HD than CAPD. This coagulopathy remained only partly corrected following successful kidney transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17496391

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  5 in total

1.  Hemostatic Parameters according to Renal Function and Time after Transplantation in Brazilian Renal Transplanted Patients.

Authors:  Ana Paula Lucas Mota; Patrícia Nessralla Alpoim; Roberta Carvalho de Figueiredo; Ana Cristina Simões e Silva; Karina Braga Gomes; Luci Maria SantAna Dusse
Journal:  Dis Markers       Date:  2015-07-01       Impact factor: 3.434

Review 2.  Haematuria in postrenal transplant patients.

Authors:  Ziting Wang; Anantharaman Vathsala; Ho Yee Tiong
Journal:  Biomed Res Int       Date:  2015-03-30       Impact factor: 3.411

3.  A Pilot Trial to Examine the Changes in Carotid Arterial Inflammation in Renal Transplant Recipients as Assessed by 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Computed Tomography (PET/CT).

Authors:  Hye Eun Yoon; Yaeni Kim; Sang Dong Kim; Jin Kyoung Oh; Yong-An Chung; Seok Joon Shin; Chul Woo Yang; Suk Min Seo
Journal:  Ann Transplant       Date:  2018-06-15       Impact factor: 1.530

4.  Hemodialysis Does Not Induce Detectable Activation of the Contact System of Coagulation.

Authors:  Karlien François; Christelle Orlando; Kristin Jochmans; Wilfried Cools; Vicky De Meyer; Christian Tielemans; Karl Martin Wissing
Journal:  Kidney Int Rep       Date:  2020-03-13

5.  The use of thromboelastography to assess post-operative changes in coagulation and predict graft function in renal transplantation.

Authors:  Carson B Walker; Hunter B Moore; Trevor L Nydam; Alexander C Schulick; Hillary Yaffe; James J Pomposelli; Michael Wachs; Thomas Bak; Kendra Conzen; Megan Adams; Thomas Pshak; Rashikh Choudhury; Michael P Chapman; Elizabeth A Pomfret; Peter Kennealey
Journal:  Am J Surg       Date:  2020-08-27       Impact factor: 2.565

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.